Xenetic Biosciences Inc
NASDAQ:XBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xenetic Biosciences Inc
NASDAQ:XBIO
|
US |
|
SORIL Infra Resources Ltd
NSE:SORILINFRA
|
IN |
|
Alphatec Holdings Inc
NASDAQ:ATEC
|
US |
|
Holcim AG
SIX:HOLN
|
CH |
|
Alexandria Real Estate Equities Inc
NYSE:ARE
|
US |
|
Blackfinch Spring VCT PLC
LSE:BFSP
|
UK |
|
L
|
Loop Telecommunication International Inc
TWSE:3025
|
TW |
|
Garudafood Putra Putri Jaya Tbk PT
IDX:GOOD
|
ID |
|
ANZ Group Holdings Ltd
OTC:ANZGF
|
AU |
Xenetic Biosciences Inc
Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The firm's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. The company uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.
Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The firm's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. The company uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.
